Dr. Zhou is a seasoned antibody drug developer. He is passionate about engineering the best-in-class biologic drugs for cancer therapy and other diseases with unmet clinical needs. He brings more than 20 years of experience in antibody discovery and engineering and bispecific antibody drug development. Dr. Zhou earned his Ph. D. in Molecular and Cell Biology at Penn State University and completed his postdoctoral training at UC Berkeley.

Dr. Zhou’s work in recombinant antibody began at the Children’s Hospital Oakland Research Institute (CHORI) with research aimed at the understanding of how the human immune system responded to vaccination. Dr. Zhou later joined Dr. Paul Carter’s lab at Genentech to develop a new bispecific antibody platform for production of bispecific antibodies in single mammalian cell line. More recently Dr. Zhou was Director of Antibody Engineering in several startup companies including Immune-Onc, CS Bay and RubRyc Therapeutics. He helped engineer a lead antibody molecule that has been advanced to Phase I clinical trial by Immune-Onc.